<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416624</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000522677</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>RC05CB</secondary_id>
    <secondary_id>06-002991</secondary_id>
    <secondary_id>EPOANE3015</secondary_id>
    <nct_id>NCT00416624</nct_id>
  </id_info>
  <brief_title>Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy</brief_title>
  <official_title>RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells.
      They are used to treat anemia caused by chemotherapy in patients with cancer.

      PURPOSE: This randomized clinical trial is studying four different schedules of epoetin alfa
      or darbepoetin alfa to compare how well they work in treating patients with anemia caused by
      chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the relative efficacy of four different erythropoietic agent dosing schedules
           comprising epoetin alfa or darbepoetin alfa, in terms of the proportion of patients with
           chemotherapy-associated anemia who achieve a weekly and overall hematopoietic response.

      Secondary

        -  Compare the effect of these regimens on the mean hemoglobin increment measured weekly
           from baseline to 15 weeks in patients with a baseline hemoglobin of less than or equal
           to 10.5 g/dL.

        -  Compare the time required to achieve hemoglobin levels within the goal range 11.0-12.0
           g/dL in patients treated with these regimens.

        -  Compare the effect of these regimens on the proportion of patients requiring red blood
           cell transfusions and on the number of transfusions required.

        -  Compare the weekly change in hemoglobin in patients treated with these regimens.

        -  Compare the need for dose reduction in patients treated with these regimens.

        -  Compare the adverse event profiles of these regimens in these patients.

        -  Compare quality of life of patients treated with these regimens.

      OUTLINE: This is a randomized, unblinded, pilot study. Patients are stratified according to
      severity of anemia (mild [hemoglobin ≥ 9.5 g/dL] vs severe [hemoglobin &lt; 9.5 g/dL]),
      platinum-containing regimen (yes vs no), and tumor type (nonmyeloid hematologic malignancy vs
      solid tumor). Patients are randomized to 1 of 4 treatment arms.

        -  Arm I: Patients receive epoetin alfa subcutaneously (SC) on day 1. Treatment repeats
           weekly for up to 15 courses in the absence of disease progression or unacceptable
           toxicity.

        -  Arm II: Patients receive epoetin alfa SC on day 1 (at a higher dose than in arm I).
           Treatment repeats every 3 weeks for up to 5 courses in the absence of disease
           progression or unacceptable toxicity.

        -  Arm III: Patients receive epoetin alfa SC on day 1 (at a higher dose than in arm II).
           Treatment repeats every 3 weeks for up to 5 courses in the absence of disease
           progression or unacceptable toxicity.

        -  Arm IV: Patients receive darbepoetin alfa SC on day 1. Treatment repeats every 3 weeks
           for up to 5 courses in the absence of disease progression or unacceptable toxicity.

      Hemoglobin levels are monitored throughout the study on a weekly basis and before each drug
      dose is administered. Drug dosing is adjusted (e.g., held, reduced, resumed at a lower dose)
      as needed to maintain hemoglobin values within the desired ranges.

      Quality of life is assessed at baseline and at weeks 4, 7, 10, 13, and 16.

      After completion of study treatment, patients are followed at 30 days.

      PROJECTED ACCRUAL: A total of 320 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Participants Who Exhibit a Hematopoietic Response</measure>
    <time_frame>20 weeks</time_frame>
    <description>A hematopoietic response was defined as Hb rise &gt;2 g/dL from baseline or achieving Hb ≥ 11.5 g/dL, whichever occurs first, in the absence of RBC transfusions within 14 days of measurement) during the treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weekly Change in Hemoglobin Levels</measure>
    <time_frame>Baseline and Week 4, 7, 10, 13, 16</time_frame>
    <description>To compare the effects of the 3 different epoetin alfa dosing schedules and an every-3-weeks darbepoetin alfa schedule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Required to Achieve Hemoglobin Levels &gt;= 11.5 g/dL</measure>
    <time_frame>16 weeks</time_frame>
    <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Hemoglobin Change From Week 1 to Week 16</measure>
    <time_frame>Week 1 and Week 16</time_frame>
    <description>To compare the effects of the 3 different epoetin alfa dosing schedules and an every-3-weeks darbepoetin alfa schedule. The positive numbers represent hemoglobin increases and negative numbers represent hemoglobin decreases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Requiring Red Blood Cell (RBC) Transfusions</measure>
    <time_frame>16 weeks</time_frame>
    <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Total RBC Transfusion Needed</measure>
    <time_frame>16 weeks</time_frame>
    <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants With Dose Omitted Due to Hematologic Reason</measure>
    <time_frame>16 Weeks</time_frame>
    <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Reported Grade 3 or 4 Adverse Events</measure>
    <time_frame>16 weeks</time_frame>
    <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. Adverse events were measured by Common Terminology Criteria for Adverse Events (CTCAE) v3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by Functional Assessment of Cancer Therapy Scales for Anemia (FACT-AN) Over All Follow-up Evaluations</measure>
    <time_frame>Weeks 4, 7, 10, 13 and 16</time_frame>
    <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. FACT-AN consist of Fatigue concerns subscale and non-fatigue concerns subscale. FACT Total Anemia score was calculated by adding the two subscales scores and transformed into 0-100 scale. FACT Total Anemia, Fatigue concerns scale and Non-Fatigue concerns scale are all ranges: 0 (Worst QOL) to 100 (Best QOL). Average scores across all time points for each subscale and total scale were calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by Linear Analogue Self Assessment Over All Follow-up Evaluation</measure>
    <time_frame>Weeks 4, 7, 10, 13 and 16</time_frame>
    <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. Linear Analogue Self Assessment (LASA) consists of 10 single-item numeric analogue scales on a scale of 0 to 10. Higher scores indicate better quality of life (QOL) on overall QOL, mental, physical, emotional spiritual QOL and Social activity; and constant pain, highest pain severity, level of fatigue and anxiety. Average scores across all time points for each item were calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by Brief Fatigue Inventory Overall All Follow-up Evaluations</measure>
    <time_frame>Weeks 4, 7, 10, 13 and 16</time_frame>
    <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. Brief Fatigue Inventory (BFI) consist of 3 single-item numeric analogue scales on a scale of 0 to 10; and an interference scale formed by 6 single-item numeric scales on a scale of 0 to 10. Higher scores indicate fatigue as bad as you can imagine for fatigue now, usual fatigue and worse fatigue; and completely interferes for BFI interference. Average scores across all time points for fatigue now, usual fatigue, worst fatigue and BFI interference subscale were calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by Symptom Distress Scale (SDS) Over All Follow-up Evaluations</measure>
    <time_frame>Weeks 4, 7, 10, 13 and 16</time_frame>
    <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. SDS Scale range: 1 (No Symptom), 5 (Worst Symptom). Average scores across all time points for each item were calculated.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">239</enrollment>
  <condition>Anemia</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoproliferative Disorder</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Precancerous Condition</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Epoetin alfa - 40000 units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40,000 Units</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epoetin alfa - 80000 units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80,000 Units</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epoetin alfa - 120000 Units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120,000 Units</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darbepoetin alfa***</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darbepoetin alfa</intervention_name>
    <arm_group_label>Epoetin alfa - 40000 units</arm_group_label>
    <arm_group_label>Epoetin alfa - 80000 units</arm_group_label>
    <arm_group_label>Epoetin alfa - 120000 Units</arm_group_label>
    <arm_group_label>Darbepoetin alfa***</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epoetin alfa</intervention_name>
    <arm_group_label>Epoetin alfa - 40000 units</arm_group_label>
    <arm_group_label>Epoetin alfa - 80000 units</arm_group_label>
    <arm_group_label>Epoetin alfa - 120000 Units</arm_group_label>
    <arm_group_label>Darbepoetin alfa***</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fatigue assessment and management</intervention_name>
    <arm_group_label>Epoetin alfa - 40000 units</arm_group_label>
    <arm_group_label>Epoetin alfa - 80000 units</arm_group_label>
    <arm_group_label>Epoetin alfa - 120000 Units</arm_group_label>
    <arm_group_label>Darbepoetin alfa***</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <arm_group_label>Epoetin alfa - 40000 units</arm_group_label>
    <arm_group_label>Epoetin alfa - 80000 units</arm_group_label>
    <arm_group_label>Epoetin alfa - 120000 Units</arm_group_label>
    <arm_group_label>Darbepoetin alfa***</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of solid tumor or nonmyeloid hematologic malignancy (e.g., plasma cell
             dyscrasia or lymphoproliferative disorder)

               -  No nonmelanomatous skin cancer

          -  Hemoglobin ≤ 10.5 g/dL

          -  Ferritin &gt; 20 ng/mL (i.e., not obviously iron deficient)

          -  Planning to receive ≥ 12 weeks of anticancer chemotherapy

               -  Biological therapy (e.g., hypomethylating agents, monoclonal antibodies, or small
                  molecule pathway inhibitors) with an individual or cumulative regimen incidence
                  of grade 3 or 4 anemia &gt; 10% is considered chemotherapy for purposes of this
                  study

          -  No known anemia secondary to any of the following:

               -  Cyanocobalamin (vitamin B_12) or folic acid deficiency

               -  Gastrointestinal bleeding within the past 2 weeks

               -  Hemolysis

               -  Myelodysplastic syndromes, myeloproliferative disorders, or acute myeloid
                  leukemia

          -  No primary hematologic disorder causing chronic moderate to severe anemia (e.g.,
             congenital dyserythropoietic anemia, homozygous hemoglobin S disease or compound
             heterozygous sickling states, or thalassemia major)

               -  Carriers of these disease states allowed provided they are not anemic prior to
                  cancer diagnosis

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy ≥ 6 months

          -  Not pregnant or nursing

               -  No delivery of a baby of ≥ 18 weeks estimated gestational age within the past 3
                  months (90 days)

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Weight &gt; 40.0 kg and &lt; 150.0 kg

          -  No known hypersensitivity to epoetin alfa, darbepoetin alfa, mammalian-cell derived
             products, or human albumin

          -  No uncontrolled hypertension, defined as systolic blood pressure (BP) ≥ 180 mm Hg
             and/or diastolic BP ≥ 100 mm Hg, despite medical therapy

          -  No pulmonary emboli and/or deep vein thrombosis within the past 12 months

               -  Patients actively receiving warfarin for a minimum of 4 weeks are exempted from
                  this requirement

               -  Prior superficial thrombophlebitis allowed

          -  No cerebrovascular accident, ischemic stroke, acute coronary syndrome (e.g., unstable
             angina or Q-wave or non-Q wave myocardial infarction), or other arterial or venous
             thrombotic events within the past 6 months

          -  No history of chronic hypercoagulable disorders (e.g., activated protein C resistance,
             anti-cardiolipin disorder, protein C deficiency, or protein S deficiency)

               -  Patients receiving anticoagulation therapy (warfarin or acetylsalicyclic acid
                  [aspirin] at a dose of ≥ 325 mg/day) for these conditions are eligible provided
                  therapy is continued during the study period

          -  History of previously treated seizures allowed provided the patient has been
             seizure-free for a minimum of 3 months

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 1 year since prior peripheral blood stem cell, bone marrow, or cord blood
             transplantation

          -  More than 14 days since prior red blood cell transfusion

          -  More than 14 days since prior major surgery, including, but not limited to, any of the
             following:

               -  Amputation

               -  Invasion of a body cavity or of the central nervous system using a scalpel, saw,
                  or laser cutting tool

               -  Resection of a body part (or parts), whether solid or liquid tissue or both, that
                  includes ≥ 1% of a patient's preoperative weight

               -  The following are not considered major surgery:

                    -  Diagnostic/therapeutic thoracentesis or paracentesis

                    -  Diagnostic skin biopsy

                    -  Digit or fingernail/thumbnail resection or laceration repair under local
                       anesthesia

                    -  Diagnostic fat aspiration

                    -  Otic irrigation to remove cerumen impaction

                    -  Tympanocentesis

                    -  Uncomplicated dental extraction

                    -  Uncomplicated tonsillectomy

                    -  Laser corneal remodeling for refraction purposes

                    -  Cosmetic or therapeutic eyelid surgery

                    -  Bone marrow aspiration and biopsy

          -  More than 10 weeks since prior darbepoetin alfa, epoetin alfa, or any investigational
             form of erythropoietin (e.g., gene-activated erythropoietin or novel erythropoiesis
             stimulating protein)

          -  No planned stem cell transplantation within the next 4 months (18 weeks)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles L. Loprinzi, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <results_first_submitted>September 10, 2015</results_first_submitted>
  <results_first_submitted_qc>December 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2017</results_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>extramedullary plasmacytoma</keyword>
  <keyword>isolated plasmacytoma of bone</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>post-transplant lymphoproliferative disorder</keyword>
  <keyword>stage I adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage II adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related primary CNS lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage I adult Hodgkin lymphoma</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>stage I adult Burkitt lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>contiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage I adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage I adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage I adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>progressive hairy cell leukemia, initial treatment</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>anemia</keyword>
  <keyword>monoclonal gammopathy of undetermined significance</keyword>
  <keyword>primary systemic amyloidosis</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>mast cell leukemia</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>untreated hairy cell leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Two hundred and thirty-nine (239) participants were enrolled at 10 Mayo Clinic Cancer Research Consortium (MCCRC) sites between February 2007 and December 2008.</recruitment_details>
      <pre_assignment_details>There were two canceled participants and 1 ineligible participants prior to study medication begins. These three participants were excluded from all analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Epoetin Alfa - 40k Weekly</title>
          <description>Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)</description>
        </group>
        <group group_id="P2">
          <title>Epoetin Alfa - 80k Every 3 Weeks</title>
          <description>Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
        </group>
        <group group_id="P3">
          <title>Epoetin Alfa - 120k Every 3 Weeks</title>
          <description>Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
        </group>
        <group group_id="P4">
          <title>Darbepoetin Alfa - 500 mcg Every 3 Weeks</title>
          <description>Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Cancel</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients that were evaluable per protocol.</population>
      <group_list>
        <group group_id="B1">
          <title>Epoetin Alfa - 40k Weekly</title>
          <description>Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)</description>
        </group>
        <group group_id="B2">
          <title>Epoetin Alfa - 80k Every 3 Weeks</title>
          <description>Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
        </group>
        <group group_id="B3">
          <title>Epoetin Alfa - 120k Every 3 Weeks</title>
          <description>Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
        </group>
        <group group_id="B4">
          <title>Darbepoetin Alfa - 500 mcg Every 3 Weeks</title>
          <description>Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="58"/>
            <count group_id="B4" value="57"/>
            <count group_id="B5" value="236"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.0" lower_limit="44.0" upper_limit="94.0"/>
                    <measurement group_id="B2" value="68.0" lower_limit="37.0" upper_limit="91.0"/>
                    <measurement group_id="B3" value="65.0" lower_limit="19.0" upper_limit="81.0"/>
                    <measurement group_id="B4" value="67.0" lower_limit="40.0" upper_limit="89.0"/>
                    <measurement group_id="B5" value="66.0" lower_limit="19.0" upper_limit="94.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="219"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anemia</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mild: Hemoglobin of 9.5-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe: Hemoglobin &lt; 9.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platinum Containing Regimen</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Tumor Type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hematologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solid Tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.6" lower_limit="149.7" upper_limit="193.0"/>
                    <measurement group_id="B2" value="168.0" lower_limit="154.0" upper_limit="201.0"/>
                    <measurement group_id="B3" value="165.2" lower_limit="150.0" upper_limit="190.0"/>
                    <measurement group_id="B4" value="166.5" lower_limit="152.4" upper_limit="187.0"/>
                    <measurement group_id="B5" value="167.0" lower_limit="149.7" upper_limit="201.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Hemoglobin</title>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.1" lower_limit="7.8" upper_limit="10.6"/>
                    <measurement group_id="B2" value="9.9" lower_limit="8.4" upper_limit="10.5"/>
                    <measurement group_id="B3" value="9.9" lower_limit="7.7" upper_limit="10.5"/>
                    <measurement group_id="B4" value="9.9" lower_limit="7.4" upper_limit="10.5"/>
                    <measurement group_id="B5" value="9.9" lower_limit="7.4" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.1" lower_limit="44.5" upper_limit="125.4"/>
                    <measurement group_id="B2" value="72.6" lower_limit="51.3" upper_limit="133.0"/>
                    <measurement group_id="B3" value="70.6" lower_limit="44.1" upper_limit="120.0"/>
                    <measurement group_id="B4" value="71.0" lower_limit="42.5" upper_limit="141.0"/>
                    <measurement group_id="B5" value="71.3" lower_limit="42.5" upper_limit="141.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Who Exhibit a Hematopoietic Response</title>
        <description>A hematopoietic response was defined as Hb rise &gt;2 g/dL from baseline or achieving Hb ≥ 11.5 g/dL, whichever occurs first, in the absence of RBC transfusions within 14 days of measurement) during the treatment period</description>
        <time_frame>20 weeks</time_frame>
        <population>All patients that were evaluable per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 40k Weekly</title>
            <description>Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa - 80k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa - 120k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O4">
            <title>Darbepoetin Alfa - 500 mcg Every 3 Weeks</title>
            <description>Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Exhibit a Hematopoietic Response</title>
          <description>A hematopoietic response was defined as Hb rise &gt;2 g/dL from baseline or achieving Hb ≥ 11.5 g/dL, whichever occurs first, in the absence of RBC transfusions within 14 days of measurement) during the treatment period</description>
          <population>All patients that were evaluable per protocol.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9"/>
                    <measurement group_id="O2" value="61.7"/>
                    <measurement group_id="O3" value="65.5"/>
                    <measurement group_id="O4" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>With 80 patients per treatment arm, there will be &gt; about 80% power to detect a difference through Fisher's exact test across two &gt; treatment arms of 25% in the true percentage of patients that experience a &gt; hematopoietic response as defined previously, if that percentage is at least 30% in &gt; the superior group, again with a 1.7% type I error rate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the hematopoietic response rate in the standard therapy group is far from 50% (&lt;25% or &gt;75%), the &gt; above sample size will provide an 80% power to detect a difference as small as &gt; 25%.</non_inferiority_desc>
            <p_value>&gt;0.41</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Change in Hemoglobin Levels</title>
        <description>To compare the effects of the 3 different epoetin alfa dosing schedules and an every-3-weeks darbepoetin alfa schedule</description>
        <time_frame>Baseline and Week 4, 7, 10, 13, 16</time_frame>
        <population>All patients that were evaluable per protocol and had hemoglobin data at baseline, week 4, 7, 10, 13 or 16.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 40k Weekly</title>
            <description>Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa - 80k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa - 120k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O4">
            <title>Darbepoetin Alfa - 500 mcg Every 3 Weeks</title>
            <description>Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Change in Hemoglobin Levels</title>
          <description>To compare the effects of the 3 different epoetin alfa dosing schedules and an every-3-weeks darbepoetin alfa schedule</description>
          <population>All patients that were evaluable per protocol and had hemoglobin data at baseline, week 4, 7, 10, 13 or 16.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 Minus Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.26"/>
                    <measurement group_id="O2" value="0.6" spread="1.02"/>
                    <measurement group_id="O3" value="0.7" spread="1.21"/>
                    <measurement group_id="O4" value="0.4" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 Minus Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.28"/>
                    <measurement group_id="O2" value="1.0" spread="1.58"/>
                    <measurement group_id="O3" value="1.1" spread="1.25"/>
                    <measurement group_id="O4" value="1.5" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 Minus Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.39"/>
                    <measurement group_id="O2" value="1.2" spread="1.42"/>
                    <measurement group_id="O3" value="1.2" spread="1.37"/>
                    <measurement group_id="O4" value="1.5" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 Minus Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.27"/>
                    <measurement group_id="O2" value="1.2" spread="1.51"/>
                    <measurement group_id="O3" value="1.3" spread="1.32"/>
                    <measurement group_id="O4" value="1.6" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 Minus Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.67"/>
                    <measurement group_id="O2" value="1.2" spread="1.64"/>
                    <measurement group_id="O3" value="1.6" spread="1.44"/>
                    <measurement group_id="O4" value="1.9" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Required to Achieve Hemoglobin Levels &gt;= 11.5 g/dL</title>
        <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule</description>
        <time_frame>16 weeks</time_frame>
        <population>All patients that were evaluable per protocol and had hemoglobin levels data.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 40k Weekly</title>
            <description>Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa - 80k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa - 120k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O4">
            <title>Darbepoetin Alfa - 500 mcg Every 3 Weeks</title>
            <description>Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Time Required to Achieve Hemoglobin Levels &gt;= 11.5 g/dL</title>
          <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule</description>
          <population>All patients that were evaluable per protocol and had hemoglobin levels data.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="28" upper_limit="37"/>
                    <measurement group_id="O2" value="50" lower_limit="35" upper_limit="68"/>
                    <measurement group_id="O3" value="49" lower_limit="35" upper_limit="77"/>
                    <measurement group_id="O4" value="49" lower_limit="35" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A sample size of 80 patients per arm will provide &gt; 80% power to detect differences between average hemoglobin levels in the &gt; reference arm and another treatment of 50% of the standard deviation. Note that &gt; typically one would expect the estimates for the standard deviation at a single time &gt; point to differ from the standard deviation for the difference from baseline.</non_inferiority_desc>
            <p_value>&gt;0.13</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Hemoglobin Change From Week 1 to Week 16</title>
        <description>To compare the effects of the 3 different epoetin alfa dosing schedules and an every-3-weeks darbepoetin alfa schedule. The positive numbers represent hemoglobin increases and negative numbers represent hemoglobin decreases.</description>
        <time_frame>Week 1 and Week 16</time_frame>
        <population>All patients that were evaluable per protocol and had hemoglobin data.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 40k Weekly</title>
            <description>Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa - 80k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa - 120k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O4">
            <title>Darbepoetin Alfa - 500 mcg Every 3 Weeks</title>
            <description>Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hemoglobin Change From Week 1 to Week 16</title>
          <description>To compare the effects of the 3 different epoetin alfa dosing schedules and an every-3-weeks darbepoetin alfa schedule. The positive numbers represent hemoglobin increases and negative numbers represent hemoglobin decreases.</description>
          <population>All patients that were evaluable per protocol and had hemoglobin data.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="1.03"/>
                    <measurement group_id="O2" value="10.3" spread="1.04"/>
                    <measurement group_id="O3" value="10.6" spread="0.8"/>
                    <measurement group_id="O4" value="10.7" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants Requiring Red Blood Cell (RBC) Transfusions</title>
        <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule</description>
        <time_frame>16 weeks</time_frame>
        <population>All patients that were evaluable per protocol and had RBC transfusions data.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 40k Weekly</title>
            <description>Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa - 80k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa - 120k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O4">
            <title>Darbepoetin Alfa - 500 mcg Every 3 Weeks</title>
            <description>Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Requiring Red Blood Cell (RBC) Transfusions</title>
          <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule</description>
          <population>All patients that were evaluable per protocol and had RBC transfusions data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="22.4"/>
                    <measurement group_id="O4" value="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>With 80 patients per treatment arm, there will be &gt; about 80% power to detect a difference through Fisher's exact test across two &gt; treatment arms of 25% in the true percentage of patients that experience a &gt; hematopoietic response as defined previously, if that percentage is at least 30% in &gt; the superior group, again with a 1.7% type I error rate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the hematopoietic response rate in the standard therapy group is far from 50% (&lt;25% or &gt;75%), the &gt; above sample size will provide an 80% power to detect a difference as small as &gt; 25%.</non_inferiority_desc>
            <p_value>&gt;0.49</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Total RBC Transfusion Needed</title>
        <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule</description>
        <time_frame>16 weeks</time_frame>
        <population>All patients that were evaluable per protocol and had RBC transfusions data.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 40k Weekly</title>
            <description>Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa - 80k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa - 120k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O4">
            <title>Darbepoetin Alfa - 500 mcg Every 3 Weeks</title>
            <description>Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>The Total RBC Transfusion Needed</title>
          <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule</description>
          <population>All patients that were evaluable per protocol and had RBC transfusions data.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="2.33"/>
                    <measurement group_id="O2" value="1.2" spread="2.67"/>
                    <measurement group_id="O3" value="0.6" spread="1.20"/>
                    <measurement group_id="O4" value="1.1" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants With Dose Omitted Due to Hematologic Reason</title>
        <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule</description>
        <time_frame>16 Weeks</time_frame>
        <population>All patients that were evaluable per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 40k Weekly</title>
            <description>Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa - 80k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa - 120k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O4">
            <title>Darbepoetin Alfa - 500 mcg Every 3 Weeks</title>
            <description>Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants With Dose Omitted Due to Hematologic Reason</title>
          <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule</description>
          <population>All patients that were evaluable per protocol.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="34.5"/>
                    <measurement group_id="O4" value="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants Reported Grade 3 or 4 Adverse Events</title>
        <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. Adverse events were measured by Common Terminology Criteria for Adverse Events (CTCAE) v3.0.</description>
        <time_frame>16 weeks</time_frame>
        <population>All patients that were evaluable per protocol and reported at least one value after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 40k Weekly</title>
            <description>Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa - 80k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa - 120k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O4">
            <title>Darbepoetin Alfa - 500 mcg Every 3 Weeks</title>
            <description>Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Reported Grade 3 or 4 Adverse Events</title>
          <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. Adverse events were measured by Common Terminology Criteria for Adverse Events (CTCAE) v3.0.</description>
          <population>All patients that were evaluable per protocol and reported at least one value after baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>With 80 patients per treatment arm, there will be about 80% power to detect a difference through Fisher's exact test across two treatment arms of 25% in the true percentage of patients that experience a hematopoietic response as defined previously, if that percentage is at least 30% in the superior group, again with a 1.7% type I error rate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the hematopoietic response rate in the standard therapy group is far from 50% (&lt;25% or &gt;75%), the above sample size will provide an 80% power to detect a difference as small as 25%.</non_inferiority_desc>
            <p_value>&gt;0.56</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by Functional Assessment of Cancer Therapy Scales for Anemia (FACT-AN) Over All Follow-up Evaluations</title>
        <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. FACT-AN consist of Fatigue concerns subscale and non-fatigue concerns subscale. FACT Total Anemia score was calculated by adding the two subscales scores and transformed into 0-100 scale. FACT Total Anemia, Fatigue concerns scale and Non-Fatigue concerns scale are all ranges: 0 (Worst QOL) to 100 (Best QOL). Average scores across all time points for each subscale and total scale were calculated.</description>
        <time_frame>Weeks 4, 7, 10, 13 and 16</time_frame>
        <population>All patients that were evaluable per protocol with QOL data.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 40k Weekly</title>
            <description>Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa - 80k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa - 120k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O4">
            <title>Darbepoetin Alfa - 500 mcg Every 3 Weeks</title>
            <description>Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by Functional Assessment of Cancer Therapy Scales for Anemia (FACT-AN) Over All Follow-up Evaluations</title>
          <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. FACT-AN consist of Fatigue concerns subscale and non-fatigue concerns subscale. FACT Total Anemia score was calculated by adding the two subscales scores and transformed into 0-100 scale. FACT Total Anemia, Fatigue concerns scale and Non-Fatigue concerns scale are all ranges: 0 (Worst QOL) to 100 (Best QOL). Average scores across all time points for each subscale and total scale were calculated.</description>
          <population>All patients that were evaluable per protocol with QOL data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FACT Fatigue Concerns</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6" spread="17.13"/>
                    <measurement group_id="O2" value="52.0" spread="20.75"/>
                    <measurement group_id="O3" value="52.6" spread="23.12"/>
                    <measurement group_id="O4" value="49.8" spread="19.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT Nonfatigue Concerns</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.6" spread="13.08"/>
                    <measurement group_id="O2" value="62.2" spread="16.64"/>
                    <measurement group_id="O3" value="61.3" spread="16.27"/>
                    <measurement group_id="O4" value="59.4" spread="13.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT Total Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" spread="14.58"/>
                    <measurement group_id="O2" value="55.6" spread="18.08"/>
                    <measurement group_id="O3" value="55.6" spread="19.85"/>
                    <measurement group_id="O4" value="53.1" spread="16.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by Linear Analogue Self Assessment Over All Follow-up Evaluation</title>
        <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. Linear Analogue Self Assessment (LASA) consists of 10 single-item numeric analogue scales on a scale of 0 to 10. Higher scores indicate better quality of life (QOL) on overall QOL, mental, physical, emotional spiritual QOL and Social activity; and constant pain, highest pain severity, level of fatigue and anxiety. Average scores across all time points for each item were calculated.</description>
        <time_frame>Weeks 4, 7, 10, 13 and 16</time_frame>
        <population>All patients that were evaluable per protocol with QOL data.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 40k Weekly</title>
            <description>Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa - 80k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa - 120k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O4">
            <title>Darbepoetin Alfa - 500 mcg Every 3 Weeks</title>
            <description>Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by Linear Analogue Self Assessment Over All Follow-up Evaluation</title>
          <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. Linear Analogue Self Assessment (LASA) consists of 10 single-item numeric analogue scales on a scale of 0 to 10. Higher scores indicate better quality of life (QOL) on overall QOL, mental, physical, emotional spiritual QOL and Social activity; and constant pain, highest pain severity, level of fatigue and anxiety. Average scores across all time points for each item were calculated.</description>
          <population>All patients that were evaluable per protocol with QOL data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall QOL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="1.59"/>
                    <measurement group_id="O2" value="6.5" spread="2.00"/>
                    <measurement group_id="O3" value="6.6" spread="2.17"/>
                    <measurement group_id="O4" value="6.1" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental QOL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="1.80"/>
                    <measurement group_id="O2" value="7.0" spread="1.97"/>
                    <measurement group_id="O3" value="7.2" spread="1.91"/>
                    <measurement group_id="O4" value="6.5" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical QOL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="1.54"/>
                    <measurement group_id="O2" value="5.8" spread="2.11"/>
                    <measurement group_id="O3" value="5.9" spread="2.22"/>
                    <measurement group_id="O4" value="5.8" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional QOL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="1.68"/>
                    <measurement group_id="O2" value="6.8" spread="1.99"/>
                    <measurement group_id="O3" value="6.7" spread="2.03"/>
                    <measurement group_id="O4" value="6.3" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Activity Level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="2.08"/>
                    <measurement group_id="O2" value="5.5" spread="2.12"/>
                    <measurement group_id="O3" value="5.4" spread="2.34"/>
                    <measurement group_id="O4" value="5.1" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spiritual QOL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="1.54"/>
                    <measurement group_id="O2" value="7.4" spread="1.81"/>
                    <measurement group_id="O3" value="7.3" spread="2.07"/>
                    <measurement group_id="O4" value="6.8" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="2.46"/>
                    <measurement group_id="O2" value="4.3" spread="2.96"/>
                    <measurement group_id="O3" value="3.9" spread="3.02"/>
                    <measurement group_id="O4" value="4.2" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.16"/>
                    <measurement group_id="O2" value="3.8" spread="2.72"/>
                    <measurement group_id="O3" value="3.7" spread="2.88"/>
                    <measurement group_id="O4" value="4.0" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="1.59"/>
                    <measurement group_id="O2" value="5.5" spread="2.02"/>
                    <measurement group_id="O3" value="5.6" spread="2.14"/>
                    <measurement group_id="O4" value="5.4" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.81"/>
                    <measurement group_id="O2" value="3.9" spread="2.20"/>
                    <measurement group_id="O3" value="4.6" spread="2.36"/>
                    <measurement group_id="O4" value="4.2" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by Brief Fatigue Inventory Overall All Follow-up Evaluations</title>
        <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. Brief Fatigue Inventory (BFI) consist of 3 single-item numeric analogue scales on a scale of 0 to 10; and an interference scale formed by 6 single-item numeric scales on a scale of 0 to 10. Higher scores indicate fatigue as bad as you can imagine for fatigue now, usual fatigue and worse fatigue; and completely interferes for BFI interference. Average scores across all time points for fatigue now, usual fatigue, worst fatigue and BFI interference subscale were calculated.</description>
        <time_frame>Weeks 4, 7, 10, 13 and 16</time_frame>
        <population>All patients that were evaluable per protocol with QOL data.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 40k Weekly</title>
            <description>Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa - 80k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa - 120k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O4">
            <title>Darbepoetin Alfa - 500 mcg Every 3 Weeks</title>
            <description>Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by Brief Fatigue Inventory Overall All Follow-up Evaluations</title>
          <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. Brief Fatigue Inventory (BFI) consist of 3 single-item numeric analogue scales on a scale of 0 to 10; and an interference scale formed by 6 single-item numeric scales on a scale of 0 to 10. Higher scores indicate fatigue as bad as you can imagine for fatigue now, usual fatigue and worse fatigue; and completely interferes for BFI interference. Average scores across all time points for fatigue now, usual fatigue, worst fatigue and BFI interference subscale were calculated.</description>
          <population>All patients that were evaluable per protocol with QOL data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue Now</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="2.25"/>
                    <measurement group_id="O2" value="4.6" spread="2.44"/>
                    <measurement group_id="O3" value="4.6" spread="2.53"/>
                    <measurement group_id="O4" value="4.7" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="2.12"/>
                    <measurement group_id="O2" value="4.7" spread="2.40"/>
                    <measurement group_id="O3" value="4.7" spread="2.53"/>
                    <measurement group_id="O4" value="4.7" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worst Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="2.17"/>
                    <measurement group_id="O2" value="5.6" spread="2.54"/>
                    <measurement group_id="O3" value="5.4" spread="2.60"/>
                    <measurement group_id="O4" value="5.3" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BFI Interference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="1.95"/>
                    <measurement group_id="O2" value="4.1" spread="2.42"/>
                    <measurement group_id="O3" value="4.3" spread="2.60"/>
                    <measurement group_id="O4" value="4.4" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by Symptom Distress Scale (SDS) Over All Follow-up Evaluations</title>
        <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. SDS Scale range: 1 (No Symptom), 5 (Worst Symptom). Average scores across all time points for each item were calculated.</description>
        <time_frame>Weeks 4, 7, 10, 13 and 16</time_frame>
        <population>All patients that were evaluable per protocol with QOL data.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 40k Weekly</title>
            <description>Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa - 80k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa - 120k Every 3 Weeks</title>
            <description>Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
          <group group_id="O4">
            <title>Darbepoetin Alfa - 500 mcg Every 3 Weeks</title>
            <description>Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by Symptom Distress Scale (SDS) Over All Follow-up Evaluations</title>
          <description>To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. SDS Scale range: 1 (No Symptom), 5 (Worst Symptom). Average scores across all time points for each item were calculated.</description>
          <population>All patients that were evaluable per protocol with QOL data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nausea Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.64"/>
                    <measurement group_id="O2" value="1.5" spread="0.67"/>
                    <measurement group_id="O3" value="1.6" spread="0.56"/>
                    <measurement group_id="O4" value="1.6" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea Severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.59"/>
                    <measurement group_id="O2" value="1.4" spread="0.62"/>
                    <measurement group_id="O3" value="1.4" spread="0.61"/>
                    <measurement group_id="O4" value="1.6" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.96"/>
                    <measurement group_id="O2" value="2.3" spread="0.94"/>
                    <measurement group_id="O3" value="2.2" spread="0.98"/>
                    <measurement group_id="O4" value="2.4" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.99"/>
                    <measurement group_id="O2" value="2.0" spread="0.88"/>
                    <measurement group_id="O3" value="2.3" spread="0.89"/>
                    <measurement group_id="O4" value="2.4" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.12"/>
                    <measurement group_id="O2" value="2.5" spread="1.15"/>
                    <measurement group_id="O3" value="2.4" spread="1.22"/>
                    <measurement group_id="O4" value="2.7" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.97"/>
                    <measurement group_id="O2" value="2.0" spread="1.02"/>
                    <measurement group_id="O3" value="2.0" spread="1.05"/>
                    <measurement group_id="O4" value="2.1" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.82"/>
                    <measurement group_id="O2" value="3.0" spread="0.94"/>
                    <measurement group_id="O3" value="2.8" spread="0.97"/>
                    <measurement group_id="O4" value="2.9" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bowel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.00"/>
                    <measurement group_id="O2" value="2.4" spread="1.20"/>
                    <measurement group_id="O3" value="2.3" spread="1.05"/>
                    <measurement group_id="O4" value="2.3" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.99"/>
                    <measurement group_id="O2" value="2.0" spread="1.00"/>
                    <measurement group_id="O3" value="1.9" spread="0.89"/>
                    <measurement group_id="O4" value="2.2" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.89"/>
                    <measurement group_id="O2" value="2.2" spread="1.05"/>
                    <measurement group_id="O3" value="2.0" spread="1.09"/>
                    <measurement group_id="O4" value="2.2" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breathing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.54"/>
                    <measurement group_id="O2" value="1.6" spread="0.64"/>
                    <measurement group_id="O3" value="1.6" spread="0.82"/>
                    <measurement group_id="O4" value="1.7" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outlook</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.98"/>
                    <measurement group_id="O2" value="2.1" spread="0.99"/>
                    <measurement group_id="O3" value="2.1" spread="0.91"/>
                    <measurement group_id="O4" value="2.4" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.77"/>
                    <measurement group_id="O2" value="1.7" spread="0.66"/>
                    <measurement group_id="O3" value="1.8" spread="0.69"/>
                    <measurement group_id="O4" value="2.0" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.64"/>
                    <measurement group_id="O2" value="1.7" spread="0.79"/>
                    <measurement group_id="O3" value="1.8" spread="0.65"/>
                    <measurement group_id="O4" value="2.0" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 Weeks</time_frame>
      <desc>All evaluable patients per protocol that reported at least one value after baseline.</desc>
      <group_list>
        <group group_id="E1">
          <title>Epoetin Alfa - 40k Weekly</title>
          <description>Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)</description>
        </group>
        <group group_id="E2">
          <title>Epoetin Alfa - 80k Every 3 Weeks</title>
          <description>Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
        </group>
        <group group_id="E3">
          <title>Epoetin Alfa - 120k Every 3 Weeks</title>
          <description>Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
        </group>
        <group group_id="E4">
          <title>Darbepoetin Alfa - 500 mcg Every 3 Weeks</title>
          <description>Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rectal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage urinary tract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Extraocular muscle paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Colonic hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Colitis, infectious (e.g., Clostridium difficile)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Infectious meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>CD4 lymphocytes decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="5" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Mini mental status examination abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Renal pelvis fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hemorrhage nasal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-and-foot syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Peripheral ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles L. Loprinzi, M.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-6247</phone>
      <email>loprinzi.charles@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

